TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06626217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting conditions
Description: The volunteers hand is at rest and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement artifacts
Description: The volunteer periodically spreads his/her fingers and clenches them into a fist, and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulation constriction
Description: The volunteers arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize. The measurement is repeated three times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The volunteer is seated on the exercise bike, rests his forearms on the handlebars and is instructed not to move his arms. The volunteer\&#39;s heart rate is controlled to increase to 120 beats per minute. For five minutes, the perfusion index is recorded from a pulse oximeter and smartwatch.
Study: NCT06624813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted partial prostatectomy
Description: Focal therapy with surgery for single lobe prostate cancer, partial robot-assisted partial prostatectomy
Study: NCT06626048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Digital cognitive behavioral therapy for insomnia (CBT-I) is a behavioral (psychotherapeutic) intervention for insomnia disorder. Participants will complete digital CBT-I online using the Sleep Healthy Using the Internet (SHUTi) program.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive Body Heating (PBH)
Description: Passive body heating (PBH) is a body-based treatment that participants will complete using a sauna blanket, which is similar in form factor to an adult-sized sleeping bag (head is not within the heated area). Participants will complete at least three 15-minute PBH sessions per week. Participants will complete PBH sessions in the sauna blanket placed on the floor or on a couch (i.e., not in their bed) at a setting of Level 6, 1-2 hours before bed.
Study: NCT06625736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical
Description: The Xenical group will receive identical capsules 120mg (one capsule) to be taken three times daily with meals, equaling 360mg total daily dose, which aligns with the usage in adult female patients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The dandelion extract
Description: The dandelion extract group will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals.
Study: NCT06625749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accurasee™ IOPCL
Description: Intraocular pseudophakic capsular lens (IOPCL)
Study: NCT06130813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: increased perioperative communication program
Description: Thanks to this communication program, informative content (8 times) will be shared with patients.
Study: NCT05056064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral exercise
Description: exercise remain tongue
Study: NCT05777954

Intervention type: OTHER
Intervention: Possible Klotho effects on SSc clinical conditions, namely skeletal, fibrotic and microangiopathic damage
Description: Female patients with a diagnosis of Systemic Sclerosis ( EULAR/ACR 2013 criteria ) attending the FPG Department of Rheumatology will be recruited after exclusion criteria are ruled out and informed consent is signed. DXA bone mineral density determination (Lunar Prodigy ) will be performed and bone metabolism parameters, according to routinary clinical practice, will be collected. Immunological and SSc-related disease features will also be recorded. Fibrosis will be determined by the extent of cutaneous involvement (limited or diffuse) and modified Rodnan Skin Score. Microangiopathy will be assessed by videocapillaroscopy and presence of acral ulcers or acrosteolysis; Presence of calcinosis will also be assessed .~Upon recruitment each SSc patient will undergo blood sampling, which will be centrifuged and stored at -80° until the day of the processing. Biomarkers (Klotho, OPG, DKK, and sclerostin) will be determined using commercial kit of the ELISA Immunoenzyme techniques

Intervention type: OTHER
Intervention: Evalution in healthy patients of bone mineral density, Klotho level and key bone-related cytokines
Description: Healthy female control patients undergoing bone mineral density determination will be recruited upon exclusion criteria are ruled out. A detailed clinical history will be assessed and blood sempling will be processed for detection of bone-related cytokines
Study: NCT05707013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HP Arize 3D-Printed Orthotics
Description: Custom 3D-printed orthotics manufactured by HP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Orthotics
Description: Traditionally fabricated custom orthotics manufactured by a local supplier.
Study: NCT05115019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI® vaccine
Description: Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological serum, 0.9% NaCl, will be used as a placebo
Study: NCT01048983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
Study: NCT06623812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Post- meal satiety and subsequent ad-libitum meal energy intake
Description: Investigate differences in post meal satiety and subsequent post meal energy intake after consuming fixed portion meals with different protein source and/ or different protein quality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Post- meal satiety and subsequent ad-libitum meal energy intake
Description: Investigate differences in post meal satiety and subsequent post meal energy intake after consuming fixed portion meals with different protein source and/ or different protein quality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Post- meal satiety and subsequent ad-libitum meal energy intake
Description: Investigate differences in post meal satiety and subsequent post meal energy intake after consuming fixed portion meals with different protein source and/ or different protein quality
Study: NCT06326996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Participants will be given an infusion of thiamine.
Study: NCT01048983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
Study: NCT06326996

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given an infusion of the placebo treatment.
Study: NCT01048983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
Study: NCT05551546

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Medicine Health Coaching for Elimination Diet for Elimination Diet
Description: All participants will receive 5 coaching sessions to support them through the elimination diet.~First session: The foundation session is where the coach and participant begin to develop rapport and outline the participant's goals. This occurs before the start of the Elimination Diet for motivation, expectations, education, and preparation.~Second session: This can occur during week 1 of the elimination diet to support working through the implementation.~Third session: This session is recommended to occur during week 3 of the diet to prepare for the reintroduction of foods.~Fourth session: A session is recommended while the participant is reintroducing foods as this is typically the most difficult part of the diet as participants may be experiencing symptoms to reactive foods.~Fifth session: A wrap up session is recommended after all of the food re-introductions to support the participant with maintenance, goals to move forward, and reflection.
Study: NCT01048983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
Study: NCT05551546

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-guided Elimination Diet
Description: The Elimination Diet course materials include self-guided materials designed to guide participants through all phases of a comprehensive elimination diet, including preparation, elimination, and reintroduction phases.~All participants in this wait-list control group will be presented via email with the opportunity to receive the five sessions of coaching (described above) at the conclusion of the study.
Study: NCT05241561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: biomonitoring and pharmacokinetics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires of quality of life
Description: FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
Study: NCT05210114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Hydration Sensor
Description: The device is a skin hydration sensor. The sensor is placed on the skin at the inner arm. It is non-invasive and measures in seconds the percent water content of the dermis by quantifying its dielectric constant.
Study: NCT05599139

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low iodine diet
Description: Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake \< 50 mcg per day and thereby depleting the overall iodine store in the body.
Study: NCT06066723

Intervention type: COMBINATION_PRODUCT
Intervention: 19F MRI
Description: Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.

Intervention type: COMBINATION_PRODUCT
Intervention: 19F MRI
Description: Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.
Study: NCT06293989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 5mg
Description: For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam 5 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Description: For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam10 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups:Placebo . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
Study: NCT01048983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
Study: NCT04910815

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Jejunal Aspiration and culture
Description: Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jejunal Aspiration and culture
Description: Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal Aspiration and culture
Description: Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin (550g) 1 capsule twice a day for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
Study: NCT05847322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bordetella pertussis B1917
Description: The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Pill
Description: A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
Study: NCT05847322

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin Pill
Description: A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
Study: NCT01048983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
Study: NCT06021938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immersive virtual reality (IVR) & Music therapy
Description: The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDA®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immersive virtual reality (IVR) & Music therapy
Description: The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDA®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).
Study: NCT03983473

Intervention type: OTHER
Group type: OTHER
Intervention: Microbiota Sequencing
Description: virome, bacteriome, fungome NGS sequencing

Intervention type: OTHER
Group type: OTHER
Intervention: Microbiota Sequencing
Description: virome, bacteriome, fungome NGS sequencing

Intervention type: OTHER
Group type: OTHER
Intervention: Microbiota Sequencing
Description: virome, bacteriome, fungome NGS sequencing

Intervention type: OTHER
Group type: OTHER
Intervention: Microbiota Sequencing
Description: virome, bacteriome, fungome NGS sequencing
Study: NCT06320236

Intervention type: DIAGNOSTIC_TEST
Intervention: Adjust-Unlikely
Description: Pulmonary embolism will be excluded during emergency department assessment by the combination of:~1. 'Pulmonary embolism is the most likely diagnosis' as per the treating physician AND a D-dimer result \< 500 ug/L fibrinogen equivalent units;~2. 'Pulmonary embolism is not the most likely diagnosis' AND D-dimer \< age-adjusted threshold; or,~3. A negative computed tomography scan, planar ventilation perfusion scan or ventilation perfusion-SPECT.~Emergency departments will use their local laboratory D-dimer assay.
Study: NCT04671381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Evaluation
Description: Behavioral thresholds for pure tones will be conducted along with speech perception measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hearing Evaluation
Description: Behavioral thresholds for pure tones will be conducted along with speech perception measures.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Evaluation
Description: Behavioral thresholds for pure tones will be conducted along with speech perception measures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-Counter Hearing Aid (OTC HA) Fitting and Orientation
Description: Study participants will be fitted with binaural OTC HAs in addition to receiving information on how to use and care for their devices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Four Weeks of Aural Rehabilitation
Description: Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Weeks of Aural Rehabilitation
Description: Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provision of Over-the-Counter Hearing Aids
Description: Study participants will receive binaural OTC HAs. Participants will fit their OTC HAs based on manufacturer guidelines without the help of an audiologist.
Study: NCT01048983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
Study: NCT06158971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible Bronchoscopic Microwave Ablation
Description: The phenoWave flexible microwave ablation system will be used to perform soft tissue ablation in the lungs under image guidance.
Study: NCT05253586

Intervention type: PROCEDURE
Intervention: Laparoscopic
Description: Surgeon

Intervention type: PROCEDURE
Intervention: Robotic
Description: Versius system